Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I haven't made up my mind about the Jan 26 options yet. They sure look attractive to me. If AVXL can't hit $10 by Jan 26 we are in deep doo doo anyway. So to me that leverage looks pretty good. The problem is I already have a bit more allocated to AVXL than I should so putting more money into it is an issue.
’26 IF I traded options might be a premium
I would be willing to play for the leverage.
15 for me was 5.50 to 6.25, but
In larger scheme I just do not see
FOMO beyond say 7 until Turkey Day.
The knee jerk to Fed certainly is not enough to propel AVXL.
It's been 3 months since the AD OLE was completed, and still no data. This CEO delays every data release and seems to have no confidence in his own work. Guy sucks, BOD need to wake up and fire him, get someone who can handle execution.
I can't help but feel that the medical industry has been largely compromised by big Pharma $$ greed and malfeasance.
Dr Angela Cenci Nilsson of Lund University in Sweden is listed as the/a researcher for Anavex 2-73 use in Parkinson's. This cites her early research for a thesis, but I can't find the follow on research the MJFF is funding. Anyone have more information on the Parkinson's study involving 2-73?
https://portal.research.lu.se/en/publications/endogenous-and-treatment-induced-neuroplasticity-in-mouse-models-
Let's hope that today's little bump was not just because of the Fed rates that were cut like let's double up and have a good day again tomorrow
Agreed, in my experience it takes a savvy blend of TA and expecting "fundamental" news that has allowed me outsized returns.
That's the way I see it, too, Tom!
Cheers, Steve
Kevin:
Just catching up!
Wishing for news is not what most TA people wait for, they normally just go with the flow and get it right a bit better than 50% of the time...
😀
Leo:
Just came in from outside, will catch up now with several messages & then will read them! Not quite certain what you mean by 15%? Do you mean a move up from the $5.50 area to $6.32? I'm using the last "hump" which was the down sweep (about 11 days ago) as the area to be surpassed as a move up towards $6.50 or so and if broken it would then, imo, open up an advance to at least $7.50.
Please go short and tell us how that works out ...very soon.
I’m glad you took the opportunity to make this subject the basis for your trolling campaign.
This batch was in-the-money short term calls.
I do have some long term calls. Jan 17 25 and am looking at the Jan 16 26 calls.
I'm about breakeven on the long term calls historically.
The 2026 calls look attractive to me.
Bullish looking follow thru bounce today, after holding 5.30 support yesterday. Climbing steps toward the 6's .Let's see
Wow. Three exclamation points is significant!!!
He did. Same as every week.
He is still looking for those signals, so NEVER...no urgency in the land of TGD.
georgejji,
When do you think we get OLE data release?
Maybe we can get our FOMO run when our MAA is accepted. We never got ours and my mom says it's not fair!
SHORT SQUEEZE for AVXL coming soon!!!
Good luck and GOD bless
Nice, you may have nailed the recent low!
I'm long Jan $5 Calls for a wee bit of leverage.
At the individual stock level I feel $6 is an important level that can be met with the broader market alone, but I think $AVXL needs a news event for any decent substantial holdable upside move, and that could come in the form of news from a PR and provide the volume needed for a positive technical move.
On the broader front, the 1/2 point USA FED cut should keep the money flowing and buoy jobs. Jobs = money moving = good economy = good equity markets at ALL market caps and dividends.
I'm watching $RUT, $XBI, $IBB, and $IBBQ for signs I'm right or wrong. But damn!!! These indexes are at or near triple and quadruple tops!?! Definitely keeping it interesting.
Expect nearly 8 million shares or more of AVXL stock to be bought this week and at a high for the week!!!
Good luck and GOD bless,
Just curious Steady....
No Options in my Roth.
Do you use in-the-money short term
Or pay the time premium on longer term trades?
Closed out my Friday $5 options by exercise.
Expect AVXL to close at or near the high of the day, today!!!
Good luck and GOD bless,
He does have significant input, as do other members of the team. That is what I already wrote.
Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%
blarcamesine (ANAVEX2-73), once daily orally, significantly slowed clinical decline in people with early Alzheimer’s disease (AD).
https://finance.yahoo.com/news/neurodegenerative-disease-focused-anavex-life-123916806.html
Kudos, george, as your prediction on interest rates are surely propelling stocks forward ... for today, at least.
No news this week. Didn't George promise?
What a potential "set up" for an advance!
The reaction to the rate cut with the very light decline provided the bulls a great reason to surprise the market today if the futures are accurate. The $IBB and $XBI look right for a big push up which might just give $AVXL a reason to move much higher (hopefully above the down slant hitting around $6.20 to $6.25 appx.
Yes, Investor where in the heck is the TLR? why is this being held up? results?
Just always remember one can only trust small trial results from Anavex and never from any other biotech - WGT!
PS! this includes of course drip fed post hoc updates often over more than a year since failed TLR.
As can be seen when viewing the following video, Dr Missling exhibits quite a deal of confidence in using blarcamesine and a treatment for Alzheimer's
https://journey.ct.events/view/b72fd686-0547-49f0-ab66-b1e4959753a1
Thank you Pasakorius on stocktwits for the link.
Good luck and GOD bless,
And you are kidding yourself if you think he doesn’t have significant input!
You are kidding yourself if you think Dr. Jin is in charge of trial design. That is not in his job title or list of responsibilities. He contributes as a member of the team, no doubt, but he is not in charge. It is clear that you have never worked in biopharm and that is OK - but your musings are not accurate.
Ken:
We recently learned that my wife who never has had ANY medical problems has just been prescribed some drops which I have to put in every day for her since they see glaucoma developing and is scheduled to see our ophthalmologist on 9/24...she was referred to someone who handles both glaucoma and cataract surgery....I had both eyes done last year for cataracts and don't require glasses for distance, just reading....give me advice if you have something I should consider.....no macular degeneration nor a vitreous hemorrhage was mentioned, this is her 3rd doctor in the office, mine said she needed to see someone else, then the new doctor referred her to this one (all in the same practice)....best, Steve
Tom:
Maybe it holds, so let's see how the next 2 days help to establish a potential inflections level! I'm just standing pat for now.
Steve
I have glaucoma, macular degeneration and a vitreous hemorrhage currently so may not be seeing clearly.
Maybe your moving avg. support line has a chance to hold now? We'll see soon enough. Price movements are not staying tight in technical trading. It's more volatile with larger moves. Up 50cents, down 50 cents.... but the whole playing field is 1 dollar (5 to 6) small, small steps, but the price is climbing and tumbling 2 and 3 steps at a time. In this range.
Anyone who didn’t doesn’t deserve an opinion.
As with my original .72 entry.
Never existed as NASDAQ listing.
Therefore.....1:4
Both the $IBB and $XBI both look better to me! ha ha.....so let's expect $AVXL to catch up....😃
Actually just realized they did a phase 2a too, though also fairly small with 48 patients.
XBI is at resistance as well. 103 has been tested several times and is a real barrier. The most advertised rate cut in history has not as yet been the catalyst so many expected. Momentum is waning in the sector but volume is not lacking.
AVXL would be considered a special situation if peer review or EMA submission were to occur. Absent any news this should go the way of XBI.
"This is a news driven stock" True - it goes down on ANY news.
That is always the question, how do macro economics affect the micro economics.
AVXL exists in a bubble right now.
The SP is controlled by the big players.
This is a news driven stock, till that changes, the players control.
Followers
|
1085
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
469806
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |